{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:40:53Z","timestamp":1764225653111,"version":"3.46.0"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Low-grade myofibroblastic sarcoma (LGMS) is a rare malignant neoplasm of the soft tissues, originating from stromal cells and accounting for approximately 1% of all malignant soft tissue tumors. It is characterized by its invasive nature, high rates of recurrence, and the presence of calcification. To date, no established treatment strategy exists for relapsed LGMS. This study aims to provide a case treated with combination regimen of palliative radiotherapy followed by toripalimab and anlotinib for LGMS patients with the second relapse, to evaluate its efficacy and safety, and to explore the impact of tumor calcification and ossification on subsequent treatment outcomes and prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This report presents the case of a 23-year-old male LGMS patient with two relapses who initially presented with post-tracheotomy status due to pharyngeal obstruction caused by masses located at the base of the tongue and floor of the mouth that had persisted for 3 weeks. He underwent palliative radiotherapy followed by toripalimab combined with anlotinib. Subsequently, surgical resection of residual lesions performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CT imaging demonstrated a significant increase in calcification and ossification of the second relapsed lesions and lymph nodes in the draining region, and stable disease with tumor shrinkage to these interventions of palliative radiotherapy followed by toripalimab combined with anlotinib. The patient was followed up until February 2025, achieving a progression-free survival 2 of 48 months from initiation of radiotherapy and an overall survival of 9 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Based on this case report, palliative radiotherapy followed by anlotinib and toripalimab may yield an acceptable therapeutic effect while being associated with manageable treatment-related adverse events in LGMS patients experiencing two relapses, who have previously undergone targeted therapy using vascular endothelial growth factor receptor-tyrosine kinase inhibitors and have not received prior radiotherapy. Nevertheless, this hypothesis requires further validation through higher-level evidence-based medical research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1606825","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:30:07Z","timestamp":1764225007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Significant increase in calcification and ossification observed after the second relapse of low-grade myofibroblast sarcoma treated with radiotherapy followed by anlotinib and toripalimab: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Juan","family":"Lang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongkui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3892\/ol.2024.14296","article-title":"Indolent growth of low\u2212grade myofibroblastic sarcoma of the knee with the resemblance of a benign lesion: A case report","volume":"27","author":"Cheng","year":"2024","journal-title":"Oncol letter"},{"key":"B2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1186\/s12891-020-03857-3","article-title":"Low-grade myofibroblastic sarcoma of the levator scapulae muscle: a case report and literature review","volume":"21","author":"Yonezawa","year":"2020","journal-title":"BMC musculoskeletal Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199810000-00008","article-title":"Low-grade myofibroblastic sarcoma: analysis of 18 cases in the spectrum of myofibroblastic tumors","volume":"22","author":"Mentzel","year":"1998","journal-title":"Am J Surg pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.13107\/jocr.2025.v15.i01.5126","article-title":"Low-grade myofibroblastic sarcoma of the acetabulum - A rare case with review of literature","volume":"15","author":"Kumar","year":"2025","journal-title":"J orthopaedic Case Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1461749","article-title":"Huge intermediate-grade myofibroblastic sarcoma in the retroperitoneum revealed by (18)F-FDG PET\/CT: a case report","volume":"11","author":"Li","year":"2024","journal-title":"Front Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/his.15196","article-title":"Recurrent USP6 rearrangement in a subset of atypical myofibroblastic tumours of the soft tissues: low-grade myofibroblastic sarcoma or atypical\/malignant nodular fasciitis","volume":"85","author":"Arcovito","year":"2024","journal-title":"Histopathology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v15.i4.566","article-title":"Low-grade myofibrosarcoma of the maxillary sinus: Two case reports","volume":"15","author":"Mydlak","year":"2024","journal-title":"World J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12880-018-0287-z","article-title":"Low-grade Myofibroblastic sarcoma: clinical and imaging findings","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Med Imag"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3000605231193929","DOI":"10.1177\/03000605231193929","article-title":"Low-grade Malignant myofibroblastic sarcoma of the larynx: a case report","volume":"51","author":"Feng","year":"2023","journal-title":"J Int Med Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"322S\u20135S","DOI":"10.1177\/01455613221145284","article-title":"Low-grade Malignant myofibroblastic sarcoma of the larynx: A case report and literature review","volume":"104","author":"Yang","year":"2022","journal-title":"Ear nose throat J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02425-4","article-title":"Is there a role for chemotherapy and radiation in the treatment of patients with low-grade myofibroblastic sarcoma","volume":"23","author":"Xu","year":"2021","journal-title":"Clin Trans Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/lary.26146","article-title":"Low-grade myofibroblastic sarcoma: A population-based study","volume":"127","author":"Chan","year":"2017","journal-title":"Laryngosc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12105-025-01783-1","article-title":"Oral and maxillofacial low-grade myofibroblastic sarcoma: A systematic review","volume":"19","author":"Giraldo-Roldan","year":"2025","journal-title":"Head Neck pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1\u201314","DOI":"10.3390\/cancers15082314","article-title":"Clinical outcome of low-grade myofibroblastic sarcoma in Japan: A multicenter study from the Japanese musculoskeletal oncology group","author":"Kito","year":"2023","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1\u201323","DOI":"10.3390\/jcm12227027","article-title":"A systematic review and illustrative case presentation of low-grade myofibroblastic sarcoma (LGMS) of the extremities","volume":"12","author":"Schenker","year":"2023","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-023-01577-3","article-title":"Low-grade myofibroblastic sarcoma of the oral and maxillofacial region: an international clinicopathologic study of 13 cases and literature review","volume":"17","author":"Giraldo-Roldan","year":"2023","journal-title":"Head Neck pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4103\/jomfp.jomfp_256_22","article-title":"Low-grade myofibroblastic sarcoma of the mandible: A rare tumour of childhood","volume":"27","author":"Mitra","year":"2023","journal-title":"J Oral Maxillofac pathol: JOMFP"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000001025","article-title":"Risk factors for recurrence and the role of radiotherapy in low-grade myofibroblastic sarcoma: A systematic review","volume":"46","author":"Mamikunian","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12957-021-02454-5","article-title":"Surgical treatment and long-term outcomes of low-grade myofibroblastic sarcoma: a single-center case series of 15 patients","volume":"19","author":"Kim","year":"2021","journal-title":"World J Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e9172","DOI":"10.1097\/MD.0000000000009172","article-title":"Low-grade myofibroblastic sarcoma of the orbit: A case report and literature review","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.048561","article-title":"Low-grade abdominopelvic sarcoma with myofibroblastic features (low-grade myofibroblastic sarcoma): clinicopathological, immunohistochemical, molecular genetic and ultrastructural study of two cases with literature review","volume":"61","author":"Agaimy","year":"2008","journal-title":"J Clin pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1139720","article-title":"Case report: Low-grade myofibroblastic sarcoma resembling lymphoma on (18)F-FDG PET\/CT","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5114\/pjp.2024.143232","article-title":"Giant low-grade myofibroblastic sarcoma of the male breast: case report and literature review","volume":"75","author":"Xiao","year":"2024","journal-title":"Polish J pathol: Off J Polish Soc Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190210","article-title":"Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx","volume":"14","author":"Sun","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41698-021-00157-4","article-title":"Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas","volume":"5","author":"Merry","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0035","article-title":"Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"von Mehren","year":"2022","journal-title":"J Natl Compr Cancer Net: JNCCN"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26415","article-title":"Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches","volume":"118","author":"Riedel","year":"2012","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e27329","DOI":"10.7759\/cureus.27329","article-title":"Outcomes of wide resection of soft-tissue sarcoma of the extremity: A retrospective analysis","volume":"14","author":"Sheoran","year":"2022","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000319","article-title":"Radiation therapy in the management of soft tissue sarcoma: A clinician\u2019s guide to timing, techniques, and targets","volume":"39","author":"Shah","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5021\/ad.21.104","article-title":"Low-grade myofibroblastic sarcoma on back with repeated localized recurrence and regional metastasis","volume":"35","author":"Park","year":"2023","journal-title":"Ann Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2005.0013","article-title":"Adjuvant therapy for soft tissue sarcoma","volume":"3","author":"Schuetze","year":"2005","journal-title":"J Natl Compr Cancer Net: JNCCN"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1\u201316","DOI":"10.3390\/cancers13030363","article-title":"The sarcoma immune landscape: emerging challenges, prognostic significance and prospective impact for immunotherapy approaches","volume":"13","author":"Koumarianou","year":"2021","journal-title":"Cancers"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01139-w","article-title":"Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study","volume":"39","author":"Tian","year":"2021","journal-title":"Investi New Drugs"},{"key":"B34","article-title":"Immunotherapeutic strategies for sarcoma: current perspectives","volume":"12","author":"Li","year":"2020","journal-title":"Am J Trans Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24647","article-title":"Apatinib as targeted therapy for sarcoma","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S359492","article-title":"Effective treatment of low-grade myofibroblastic sarcoma with apatinib: A case report and literature review","volume":"15","author":"Lin","year":"2022","journal-title":"Pharmacogenom Personal Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.eclinm.2023.102240","article-title":"Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial","volume":"64","author":"Xu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03259-5","article-title":"Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients","volume":"72","author":"Yuan","year":"2023","journal-title":"Cancer immunol immunother: CII"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.895982","article-title":"The effect of anlotinib combined with anti-PD-1 in the treatment of gastric cancer","volume":"9","author":"Zheng","year":"2022","journal-title":"Front surg"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e11004","DOI":"10.1097\/MD.0000000000011004","article-title":"Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis","volume":"97","author":"Zheng","year":"2018","journal-title":"Medicine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1609804","DOI":"10.3389\/pore.2021.1609804","article-title":"Prevalence and prognostic implications of PD-L1 expression in soft tissue sarcomas","volume":"27","author":"Kelany","year":"2021","journal-title":"Pathol Oncol res: POR"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573202","article-title":"Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report","volume":"16","author":"Lang","year":"2025","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"151823","DOI":"10.1016\/j.anndiagpath.2021.151823","article-title":"PD-L1 expression in sarcomas: An immunohistochemical study and review of the literature","volume":"55","author":"Cunningham","year":"2021","journal-title":"Ann Diagn pathol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12967-018-1658-5","article-title":"Status of programmed death-ligand 1 expression in sarcomas","volume":"16","author":"Park","year":"2018","journal-title":"J Trans Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-023-01486-6","article-title":"New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting","volume":"16","author":"Roulleaux-Dugage","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303383","article-title":"Atezolizumab for advanced alveolar soft part sarcoma","volume":"389","author":"Chen","year":"2023","journal-title":"New Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-020-00891-5","article-title":"PD1\/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials","volume":"13","author":"Italiano","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1603855","article-title":"Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy","volume":"16","author":"Kansha","year":"2025","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18632\/aging.206020","article-title":"High expression of circulating exosomal PD-L1 contributes to immune escape of hepatocellular carcinoma and immune clearance of chronic hepatitis B","volume":"16","author":"Lin","year":"2024","journal-title":"Aging"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2174\/0118715206340244250605061005","article-title":"Determination of PD-L1 expression in circulating tumor cells of hypopharyngeal and laryngeal cancers and correlation with tissue detection","author":"Li","year":"2025","journal-title":"Anti-cancer Agents med Chem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1473897","article-title":"Suppression of MCP-1, IFN-gamma and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival","volume":"15","author":"Wellhausen","year":"2024","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820715)50:2<345::AID-CNCR2820500231>3.0.CO;2-Y","article-title":"Calcifying synovial sarcoma","volume":"50","author":"Varela-Duran","year":"1982","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-022-09049-y","article-title":"Prognostic factors of the synovial sarcoma of the extremities: imaging does matter","volume":"33","author":"Tordjman","year":"2023","journal-title":"Eur radiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/00004728-200309000-00019","article-title":"Primary dedifferentiated liposarcoma of the retroperitoneum","volume":"27","author":"Tateishi","year":"2003","journal-title":"Progn signif comput tomograp magnet resonan Imaging feature J Comput assist tomograp"},{"key":"B56","doi-asserted-by":"publisher","first-page":"106752","DOI":"10.1016\/j.crad.2024.106752","article-title":"A pictorial review of osseous and cartilaginous soft tissue tumours","volume":"80","author":"Crompton","year":"2025","journal-title":"Clin radiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90276-3","article-title":"Primary synovial chondromatosis: a clinicopathologic review and assessment of Malignant potential","volume":"29","author":"Davis","year":"1998","journal-title":"Hum pathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/his.13421","article-title":"Osteogenic differentiation in dedifferentiated liposarcoma: a study of 36 cases in comparison to the cases without ossification","volume":"72","author":"Yamashita","year":"2018","journal-title":"Histopathology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e1442168","DOI":"10.1080\/2162402X.2018.1442168","article-title":"Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma","volume":"7","author":"Patel","year":"2018","journal-title":"Oncoimmunology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.02.029","article-title":"The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions","volume":"46","author":"Lee","year":"2020","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2527\u201339","DOI":"10.1097\/CM9.0000000000003609","article-title":"Immunotherapy and radiotherapy: An effective combination in cancer treatment","volume":"138","author":"Li","year":"2025","journal-title":"Chin Med J"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.12.032","article-title":"Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3","volume":"495","author":"Zheng","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-021-02069-4","article-title":"Apatinib triggers autophagic and apoptotic cell death via VEGFR2\/STAT3\/PD-L1 and ROS\/Nrf2\/p62 signaling in lung cancer","volume":"40","author":"Xie","year":"2021","journal-title":"J Exp Clin Cancer res: CR"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0725","article-title":"Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice","volume":"16","author":"Duan","year":"2020","journal-title":"Future Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2021.1526","article-title":"PD-L1 upregulation by the mTOR pathway in VEGFR-TKI-resistant metastatic clear cell renal cell carcinoma","volume":"55","author":"Jeong","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e157347","DOI":"10.1172\/jci.insight.157347","article-title":"Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma","volume":"8","author":"Tran","year":"2023","journal-title":"JCI Insight"},{"key":"B67","doi-asserted-by":"publisher","first-page":"112655","DOI":"10.1016\/j.yexcr.2021.112655","article-title":"YAP\/STAT3 promotes the immune escape of larynx carcinoma by activating VEGFR1-TGFbeta signaling to facilitate PD-L1 expression in M2-like TAMs","volume":"405","author":"Du","year":"2021","journal-title":"Exp Cell Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12157","article-title":"Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN\/VEGFR2 signaling axis in ovarian cancer","volume":"41","author":"Yang","year":"2021","journal-title":"Cancer Commun"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.754","article-title":"Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma","volume":"5","author":"Fukuda","year":"2016","journal-title":"Cancer Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e0268244","DOI":"10.1371\/journal.pone.0268244","article-title":"Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models","volume":"17","author":"Li","year":"2022","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i35.8385","article-title":"Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report","volume":"11","author":"Wu","year":"2023","journal-title":"World J Clin cases"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683502","article-title":"Anlotinib combined with anti-PD-1 antibodies therapy in patients with advanced refractory solid tumors: A single-center, observational, prospective study","volume":"11","author":"Yuan","year":"2021","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12885-016-2451-6","article-title":"Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma","volume":"16","author":"Kim","year":"2016","journal-title":"BMC can"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1606825\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:30:08Z","timestamp":1764225008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1606825\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":73,"alternative-id":["10.3389\/fimmu.2025.1606825"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1606825","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"article-number":"1606825"}}